Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878320 | 0.79 | ALDH1A1 (0.33) | FFAR3ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL4481064 | 0.78 | RNPEP (0.35) | ALDH1A1 | |
| SCHEMBL4478271 | 0.76 | RNPEP (0.34) | ALDH1A1 | |
| SCHEMBL11108269 | 0.73 | ALDH1A1 (0.33) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28465608 | 0.73 | — | — | |
| SCHEMBL9273470 | 0.72 | CYP2C19 (0.46) | FFAR3ALDH1A1 | |
| SCHEMBL28674776 | 0.71 | FDPS (0.41) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL288789 | 0.71 | FDPS (0.41) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL2235565 | 0.70 | — | — | |
| SCHEMBL5689354 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173700-B1 | METHOD FOR THE PRODUCTION OF KETOACIDS AND THEIR DERIVATIVES | EVONIK DEGUSSA GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2173700-B1 | METHOD FOR THE PRODUCTION OF KETOACIDS AND THEIR DERIVATIVES | EVONIK DEGUSSA GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| US-8299293-B2 | Process for preparing α-keto acids and derivatives thereof | EVONIK DEGUSSA GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299293-B2 | Process for preparing α-keto acids and derivatives thereof | EVONIK DEGUSSA GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299293-B2 | Process for preparing α-keto acids and derivatives thereof | EVONIK DEGUSSA GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20090076302-A1 | PROCESS FOR PREPARING a-KETO ACIDS AND DERIVATIVES THEREOF | EVONIK DEGUSSA GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076302-A1 | PROCESS FOR PREPARING a-KETO ACIDS AND DERIVATIVES THEREOF | EVONIK DEGUSSA GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076302-A1 | PROCESS FOR PREPARING a-KETO ACIDS AND DERIVATIVES THEREOF | EVONIK DEGUSSA GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009007193-A1 | METHOD FOR THE PRODUCTION OF KETOACIDS AND THEIR DERIVATIVES | EVONIK DEGUSSA GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076302-A1 | PROCESS FOR PREPARING a-KETO ACIDS AND DERIVATIVES THEREOF | BCKDK, KHK, ADSL | FFAR3 2047/4885HDAC3 4393/4885HDAC1 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.